Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Histologically confirmed glioblastoma multiforme or gliosarcoma~* Recurrent disease with an:~  * interval of at least 3 months following initial radiotherapy and temozolomide~ * interval of at least 3 weeks between end of surgery for recurrent disease and start of protocol therapy for patients who have undergone surgery for recurrent disease~* KPS 60% or higher~* Adequate bone marrow function Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 14 days prior to study initiation.~* Women of childbearing potential must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment.~* Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment.~Exclusion Criteria~* Histology other than astrocytoma grade IV (GBM or gliosarcoma)~* Tumor foci below the tentorium or or beyond the cranial vault~* Glioblastoma or gliosarcoma disease with leptomeningeal spread~* Patients with a history of any other cancer, unless in complete remission, and off all therapy for that disease for a minimum of 5 years~* Elevated serum aspartate aminotransferase, alanine aminotransferase, or bilirubin (unless there is medical justification for bilirubin elevation, and aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase are normal)~* Moderate to severe hepatic impairment~* Confirmed systolic blood pressure \< 100 mmHg or diastolic blood pressure \< 50 mmHg~* History of orthostatic hypotension~* Renal insufficiency or serum creatinine above the normal reference range~* Prior chemotherapy for recurrent glioblastoma with nitrosourea compounds or bevacizumab~* Prior focal radiotherapy~* Severe, active co-morbidity (e.g. cardiac disease; respiratory disease; chronic hepatitis; hematological and bone marrow diseases; severe malabsorption)~* No other active cancer~* No concurrent cytochrome P450 3A4 inducers~* No concurrent strong cytochrome P450 3A4 inhibitors~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan in combination with dose-dense temozolomide

Based on this trial design, predict the completion outcome and termination type (if applicable).